

Applicants: Arlindo L. Castelhano et al.
Serial No.: Not Yet Known
Filed : Herewith
Page 12

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on Form PTO-1449 (**Exhibit B**) and are also listed below.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Information Disclosure Statement should be entered and considered.

The above-identified application claims benefit under 35 U.S.C. §120 of Serial No. 10/000,280 (U.S. Application Publication No. 2003-0045536-A1), filed November 30, 2001. Copies of the documents listed below as references 1-46 and 50-110 have previously been submitted to, or cited by the U.S. Patent Office in connection with Serial No. 10/000,280. Therefore, in accordance with 37 C.F.R. §1.98(d), copies of the previously submitted documents are not provided. A copy of reference 48 is not provided because the disclosure of this reference is substantively cumulative with the disclosure of the reference listed below as item 47, a copy of which is provided herewith. A copy of each of the references listed below as items 47 and 49 is attached hereto as **Exhibits 1 and 2**.

Pursuant to 37 C.F.R. 1.98(a), applicants have listed on Form PTO-1449 copending U.S. applications and have listed them below

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 13

as references 102-110. Applicants also enclose copies of the claims as allowed or as currently pending in each of the copending U.S. applications as **Exhibits 3-10**. The claims for U.S. Application No. 10/010,092 are the same as those originally filed in that application. Consequently, a copy of the claims is not enclosed.

Applicants also disclose to the Examiner that they are filing concurrently with the subject application another continuation application of U.S. Serial No. 10/000,280, which will bear attorney Docket No. "60390-IA". Applicants at this time do not have the Serial No. for the concurrently filed continuation application, but respectfully request that the Examiner consider the concurrently filed continuation application and enter it on a Notice of References Cited which will be forwarded to applicants.

For the convenience of the Examiner, applicants point out that references 1, 24, 25, 32, 41, 42, 51-57, 74, 77, 79, 84, 85, 95 and 97 were cited in a corresponding PCT International Search Report for PCT International Publication No. WO 99/62518; reference 2 was cited in a corresponding PCT International Search Report for PCT International Publication No. WO 01/39777; references 68 and 73 were cited by the U.S. Patent Office in connection with U.S. Application No. 09/454,075; and references 35 and 83 were cited in the corresponding PCT Preliminary Examination Report for PCT International Publication No. WO 99/62518. A copy of the aforementioned search reports can be

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 14

found with the copy of the PCT International Publication No. WO 99/62518 submitted in connection with U.S. Serial No. 10/000,280, and with the copy of PCT International Publication No. WO 01/39777 submitted as Exhibit 1. A copy of the PCT Preliminary Examination Report for PCT International Publication No. WO 99/62518 is attached hereto as **Exhibit C**.

1. U.S. Patent No. 3,037,980, issued June 5, 1962, Hitchings, G. H. et al.;
2. U.S. Patent No. 3,910,913, issued October 7, 1975, Kim, et al.;
3. U.S. Patent No. 5,208,240, issued May 4, 1993, Peet et al.;
4. U.S. Patent No. 5,409,930, issued April 25, 1995, Spada, A. P. et al.;
5. U.S. Patent No. 5,516,894, issued May 14, 1996, Reppert, S. M.;
6. U.S. Patent No. 5,580,870, issued December 3, 1996, Barker, A. J. et al.;
7. U.S. Patent No. 5,639,913, issued June 17, 1997, Lidor et al.;
8. U.S. Patent No. 5,646,156, issued July 8, 1997, Jacobson,

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 15

et al.;

9. U.S. Patent No. 5,681,941, issued October 28, 1997, Cook,
P. D. et al.;

10. U.S. Patent No. 5,710,158, issued January 20, 1998, Myers,
M. R. et al.;

11. U.S. Patent No. 5,714,493, issued February 3, 1998, Myers,
M. R. et al.;

12. U.S. Patent No. 5,721,237, issued February 24, 1998, Myers,
M. R. et al.;

13. U.S. Patent No. 5,747,498, issued May 5, 1998, Schnur, R.
C. et al.;

14. U.S. Patent No. 5,780,450, issued July 14, 1998, Shade, D.
L.;

15. U.S. Patent No. 5,780,481, issued July 14, 1998, Jacobson,
et al.;

16. U.S. Patent No. 5,834,609, issued November 10, 1998, Horne,
D. A. et al.;

17. U.S. Patent No. 5,877,218, issued March 2, 1999, Herzog et
al.;

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 16

18. U.S. Patent No. 5,877,221, issued March 2, 1999, Cohen et al.;
19. U.S. Patent No. 5,880,159, issued March 9, 1999, Herzog et al.;
20. U.S. Patent No. 5,914,349, issued June 22, 1999, Cohen et al.;
21. U.S. Patent No. 5,962,458, issued October 5, 1999, Lohmann, et al.;
22. U.S. Patent No. 5,994,408, issued November 30, 1999, Cohen et al.;
23. U.S. Patent No. 6,103,899, issued August 15, 2000, Horne, D. A. et al.;
24. PCT International Publication No. WO 93/20078, published October 14, 1993;
25. PCT International Publication No. WO 94/13676, published June 23, 1994;
26. PCT International Publication No. WO 94/17090, published August 4, 1994;

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 17

27. PCT International Publication No. WO 94/19349, published September 1, 1994;
28. PCT International Publication No. WO 94/24136, published October 27, 1994;
29. PCT International Publication No. WO 95/11681, published May 4, 1995;
30. PCT International Publication No. WO 95/18617, published July 13, 1995;
31. PCT International Publication No. WO 95/19774, published July 27, 1995;
32. PCT International Publication No. WO 95/19970, published July 27, 1995;
33. PCT International Publication No. WO 95/20597, published August 3, 1995;
34. PCT International Publication No. WO 96/19478, published June 27, 1996;
35. PCT International Publication No. WO 97/02266, published January 23, 1997;
36. PCT International Publication No. WO 97/05138, published

Applicants: Arlindo L. Castelhano et al.
Serial No.: Not Yet Known
Filed : Herewith
Page 18

February 13, 1997;

37. PCT International Publication No. WO 97/33879, published September 18, 1997;
38. PCT International Publication No. WO 98/07726, published February 26, 1998;
39. PCT International Publication No. WO 98/08382, published March 5, 1998;
40. PCT International Publication No. WO 98/22465, published May 28, 1998;
41. PCT International Publication No. WO 98/29397, published July 9, 1998;
42. PCT International Publication No. WO 98/57651, published December 23, 1998;
43. PCT International Publication No. WO 99/06053, published February 11, 1999;
44. PCT International Publication No. WO 99/33815, published July 8, 1999;
45. PCT International Publication No. WO 99/42093, published August 26, 1999;

Applicants: Arlindo L. Castelhano et al.
Serial No.: Not Yet Known
Filed : Herewith
Page 19

46. PCT International Publication No. WO 99/62518, published December 9, 1999;
47. PCT International Publication No. WO 01/39777, published June 7, 2001 (**Exhibit 1**);
48. PCT International Publication No. WO 02/057267, published July 25, 2002;
49. PCT International Publication No. WO 03/048120, published June 12, 2003 (**Exhibit 2**);
50. European Patent Application No. EP 322 242 A2, published June 28, 1989;
51. European Patent Application No. EP 0 514 540 A1, published November 25, 1992;
52. European Patent Application No. EP 0 682 027 A1, published November 15, 1995;
53. European Patent Application No. EP 0 729 758 A2, published September 4, 1996;
54. European Patent Application No. EP 0 773 023 A1, published May 14, 1997;

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 20

55. Great Britain Patent Application No. 915,303, published January 9, 1963;
56. German Patent Application No. DE 31 45 287 A1, published May 19, 1993;
57. Indian Application No. 157280, published February 22, 1986;
58. Japanese Patent Application No. JP 09-291089, published May 11, 1999;
59. Abbracchio M., et al., (1999) "Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases", Ann. NY. Acad. Sci., 890: 79-92;
60. Banker, G.S. et al., Modern Pharmaceutics, 3rd ed., Marcel Dekker, New York, 1996, page 596;
61. Barrett, R.J. (1996) "Realizing the Potential of Adenosine-Receptor-Based Therapeutics" Proc. West. Pharmacol. Soc. 39: 61-66;
62. Barrett, R.J. et al., "N-0861 selectively antagonizes adenosine A1 receptors in vivo" European J. Pharmacology (1992) 216: 9-16;
63. Brand A., et al., (2001) "Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 21

neurons", Neuropharmacology, 40: 85-95;

64. Bundy, G.L. et al. (1995) "Synthesis of Novel 2,4-Diaminopyrrolo-[2,3-d]pyrimidines with Antioxidant, Neuroprotective, and Antiasthma Activity" J. Med. Chem. 38: 4161-4163;
65. Campbell, R.M. et al., "Selective A₁-Adenosine Receptor Antagonists Identified Using Yeast *Saccharomyces Cerevisiae* Functional Assays" Bioorg. & Med. Chem. Lett. (1999) 9(16): 2413-2418;
66. Chen, Y. L., et al., "Synthesis and Oral Efficacy of a 4-(Butylethylamino)pyrrolo[2,3-d]pyrimidine: A Centrally Active Corticotropin-Releasing Factor₁ Receptor Antagonist", (1997) J. Med. Chem., 40: 1749-1754;
67. Cummings, J. et al., "Antagonism of the Cardiodepressant Effects of Adenosine during Acute Hypoxia" Academic Emergency Medicine (2000), 7(8): 618-624;
68. DeNinno, M.P. in Annual Reports in Medicinal Chemistry, Vol. 33, (Academic Press: San Diego, 1998), pp. 111-120;
69. Dhainaut, A. et al., "New Purines and Purine Analogs as Modulators of Multidrug Resistance" J. Med. Chem. (1996) 39: 4099-4108;

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 22

70. Dooley, M.J. et al., "Theoretical Structure-Activity Studies of Adenosine A₁ Ligands: Requirements for Receptor Affinity" *Bioorg. Med. Chem.* (1996), 4(6): 923-934;
71. Feoktistove, I. et al., (1998) "Adenosine A_{2B} receptors: a novel therapeutic target in asthma?", TiPS 19: 148-153;
72. Gao, E. et al., "Adenosine A₁ Receptor Antagonist Prolongs Survival in the Hypoxic Rat" *J. Cardiovascular Pharm.* (2001) 38: 384-394;
73. Hart, H. et al., Organic Chemistry, A Short Course, (Houghton Mifflin: 1995), p. 121;
74. Iwamura, H. et al. (1996) "Quantitative Aspects of the Receptor Binding of Cytokinin Agonists and Antagonists" J. Med. Chem., 26: 838-844;
75. Jacobson K.A., et al., (1998) "Adenosine A₃ receptors: novel ligands and paradoxical effects", TiPS, 19:184-191;
76. Jacobson K.A., et al., (1997) "Pharmacological Characterization of Novel A₃ Adenosine Receptor-selective Antagonists", Neuropharmacology, 36 (9): 1157-1165;
77. Jorgensen, A. et al. (1985) "Synthesis of 7H-Pyrrolo[2,3-d]pyrimidin-4-amines" Liebigs, Ann. Chem., Pages 142-148;

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 23

78. Kaiser, S.M. and R.J. Quinn (1999) "Adenosine receptors as potential therapeutic targets" Drug Discovery Today 4(12): 542-551;
79. Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" (1961) Yakugaku Zasshi 81: 1650-1653;
80. Lee T., et al., (1999) "Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors", 72nd Scientific Sessions of the American Heart Association, Atlanta, GA, p.197;
81. Lee T., et al., (2000) "Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors", Am. J. Physiol. Renal Physiol., 278: F380-F387;
82. Marx, D. et al. (2001) "Therapy of Bronchial Asthma with Adenosine Receptor Agonists or Antagonists" Drug News Perspect. 14(2): 89-100;
83. Mautner, H.G., (1961) "Potential Deoxyribonucleic Acid Cross-linking Agents. 8,8'-Bispurines", J. Org. Chem. 26(6):1914-1917;
84. Muller, C. E. et al. (1990) "7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A1 Selective

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 24

Adenosine Receptor Antagonists" J. Med. Chem., 33: 2822-2828;

85. Muller, C.E. et al. (1996) "Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A₁-Adenosine Receptor Antagonists" J. Med. Chem., 39: 2482-2491;
86. Muller, C. E. and Stein, B. (1996) "Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications", Current Pharmaceutical Design, 2: 501-530;
87. Muller, C. E. (1997) "A₁-Adenosine Receptor Antagonists", Exp. Opin. Ther. Patents 7(5): 419-440;
88. Muller, C. E., et al., (1997) "Synthesis and Structure-Activity Relationships of 3,7-Dimethyl-1-propargylxanthine Derivatives, A_{2A}-Selective Adenosine Receptor Antagonists", J. Med. Chem., 40: 4396-4405;
89. Nishiyama, A. et al., "Adenosine A1 Receptor Antagonist KW-3902 Prevents Hypoxia-Induced Renal Vasoconstriction" J. Pharm. Exp. Ther. (1999), 291: 988-993;
90. Nyce, J. W. and Metzger, J.W., (1997) "DNA antisense therapy for asthma in an animal model", Nature, 385: 721-725;

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 25

91. Pichler, H. et al. "Synthese von 7-unsubstituierten 7H-Pyrrolo[2,3-d] pyrimidinen", (1986) Liebigs Ann. Chemie., 9: 1485-1505;
92. Seela, F., and Lupke, U., "Mannich-Reaktion am 2-Amino-3,7-dihydropyrrolo [2,3-d] pyrimidin-4-on, dem Chromophor des Ribonucleosids "Q" (1977) Chem. Ber. 110: 1462-1469;
93. Shan, Daxian et al., J. Pharmaceutical Sci., (1997) 86:765-767;
94. Szkotak, A.J. et al., "Regulation of K⁺ current in human airway epithelial cells by exogenous and autocrine adenosine" Am. J. Physiol. Cell Physiol. (2001), 281: C1991-C2002;
95. Venugopalan, B. et al. (1998) "Synthesis of 6,7-Dimethoxypyrimido[4,5-b]-indoles as Potential Antihypertensive Agents" J. Heterocyclic Chem., 25: 1633-1639;
96. Welch, W.J. "Adenosine type 1 receptor antagonists in fluid retaining disorders" Expert Opin. Investig. Drugs (2002), 11(11): 1553-1562;
97. West, R. A. et al. (1961) "2-Alkyl(aryl)-and 2,7-Dimethyl-4-substituted Aminopyrrolo[2,3-d]pyrimidines" J. Org. Chem., 26: 3809-3812;

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 26

98. Williams, E. F. et al., "Nucleoside transport sites in a cultured human retinal cell line established by SV-40 T antigen gene", (1994) Current Eye Research, 13: 109-118;
99. Wolff, Manfred E., Burger's Medicinal Chemistry and Drug Discovery, 5th ed., Volume I: Principles and Practice, John Wiley & Sons, 1995, pages 975-977;
100. Woods, C. L. and Blazynski, C. (1991) "Characterization of Adenosine A₁-receptor Binding Sites in Bovine Retinal Membranes", Experimental Eye Research, 53: 325-331;
101. Zhao, Z. et al., "Bioactivation of 6,7-Dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) to Reactive Intermediates that Bind Covalently to Macromolecules and Produce Genotoxicity" Chem. Res. Toxicol., (1996) 9: 1230-1239;
102. U.S. Patent Application Publication No. US-2002-0028782-A1, published March 7, 2002, Castelhano et al. (**Exhibit 3 - claims only**);
103. U.S. Patent Application Publication No. US-2002-0058667-A1, published May 16, 2002, Castelhano et al. (**Exhibit 4 - claims only**);
104. U.S. Patent Application Publication No. US-2003-0036545-A1,

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 27

published February 20, 2003, Castelhano et al. (**Exhibit 5 - claims only**);

105. U.S. Patent Application Publication No. US-2002-0094974-A1, published July 18, 2002, Castelhano et al. (**Exhibit 6 - claims only**);

106. U.S. Patent Application Publication No. US-2003-0073708-A1, published April 17, 2003, Castelhano et al. (**Exhibit 7 - claims only**);

107. U.S. Patent Application Serial No. 09/454,074, filed December 2, 1999, Castelhano et al. (**Exhibit 8 - claims only**);

108. U.S. Patent Application Serial No. 09/454,075, filed December 2, 1999, Castelhano et al. (**Exhibit 9 - claims only**);

109. U.S. Patent Application Serial No. 10/010,092, filed November 30, 2001, Castelhano et al.; and

110. U.S. Patent Application Publication No. US-2003-0045536-A1, published March 6, 2003, Castelhano et al. (**Exhibit 10 - claims only**).

Applicants request that the Examiner review the references and make them of record in the subject application.

Applicants: Arlindo L. Castelhano et al.

Serial No.: Not Yet Known

Filed : Herewith

Page 28

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment and Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White

Registration No. 28,678

Gary J. Gershik

Registration No. 39,992

Attorneys for Applicants

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

(212) 278-0400

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office							Atty. Docket No. 60390-IB/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									Applicants: Arlindo Castelhano et al.	
									Filing Date Herewith	Group
U.S. PATENT DOCUMENTS										
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate
		3	0	3	7	9	8	0	6/5/62	Hitchings, G.H. et al.;
		3	9	1	0	9	1	3	10/7/75	Kim, et al.;
		5	2	0	8	2	4	0	5/4/93	Peet, et al.;
		5	4	0	9	9	3	0	4/25/95	Spada, A.P. et al.;
		5	5	1	6	8	9	4	5/14/96	Reppert, S.M.;
		5	5	8	0	8	7	0	12/3/96	Barker, A.J. et al.;
		5	6	3	9	9	1	3	6/17/97	Lidor et al.;
		5	6	4	6	1	5	6	7/8/97	Jacobson et al.;
		5	6	8	1	9	4	1	10/28/97	Cook, P.D. et al.;
		5	7	1	0	1	5	8	1/20/98	Myers, M.R. et al.;
		5	7	1	4	4	9	3	2/3/98	Myers, M.R. et al.;
		5	7	2	1	2	3	7	2/24/98	Myers, M.R. et al.;
		5	7	4	7	4	9	8	5/5/98	Schnur, R.C. et al.;
		5	7	8	0	4	5	0	7/14/98	Shade, D.L. et al.;
		5	7	8	0	4	8	1	7/14/98	Jacobson et al.;
		5	8	3	4	6	0	9	11/10/98	Horne, D.A. et al.;
		5	8	7	7	2	1	8	3/2/99	Herzig et al.;
		5	8	7	7	2	2	1	3/2/99	Cohen et al.;
		5	8	8	0	1	5	9	3/9/99	Herzig et al.;
		5	9	1	4	3	4	9	6/22/99	Cohen et al.;
		5	9	6	2	4	5	8	10/5/99	Lohmann et al.;
		5	9	9	4	4	0	8	11/30/99	Cohen et al.;
		6	1	0	3	8	9	9	8/15/00	Horne, D.A. et al.
FOREIGN PATENT DOCUMENTS										
		Document Number				Date	Country	Class	Subclass	Translation
										Yes No
	WO	9	3	2	0	0	7	8	10/14/93	PCT;
	WO	9	4	1	3	6	7	6	6/23/94	PCT;
	WO	9	4	1	7	0	9	0	8/4/94	PCT;
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
EXAMINER					DATE CONSIDERED					
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office								Atty. Docket No. 60390-IB/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										Applicants: Arlindo Castelhano et al.	
										Filing Date Herewith	Group
U.S. PATENT DOCUMENTS											
Examiner Initial		Document Number				Date	Name		Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS											
WO	9	4	1	9	3	4	9	9/1/94	PCT;		
WO	9	4	2	4	1	3	6	10/27/94	PCT;		
WO	9	5	1	1	6	8	1	5/4/95	PCT;		
WO	9	5	1	8	6	1	7	7/13/95	PCT;		
WO	9	5	1	9	7	7	4	7/27/95	PCT;		
WO	9	5	1	9	9	7	0	7/27/95	PCT;		
WO	9	5	2	0	5	9	7	8/3/95	PCT;		
WO	9	6	1	9	4	7	8	6/27/96	PCT;		
WO	9	7	0	2	2	6	6	1/23/97	PCT;		
WO	9	7	0	5	1	3	8	2/13/97	PCT;		
WO	9	7	3	3	8	7	9	9/18/97	PCT;		
WO	9	8	0	7	7	2	6	2/26/98	PCT;		
WO	9	8	0	8	3	8	2	3/5/98	PCT;		
WO	9	8	2	2	4	6	5	5/28/98	PCT;		
WO	9	8	2	9	3	9	7	7/9/98	PCT;		
WO	9	8	5	7	6	5	1	12/23/98	PCT;		
WO	9	9	0	6	0	5	3	2/11/99	PCT;		
WO	9	9	3	3	8	1	5	7/8/99	PCT;		
WO	9	9	4	2	0	9	3	8/26/99	PCT;		
WO	9	9	6	2	5	1	8	12/9/99	PCT;		
WO	0	1	3	9	7	7	7	6/7/01	PCT (Exhibit 1);		
WO	02	0	5	7	2	6	7	7/25/02	PCT;		
WO	03	0	4	8	1	2	0	6/12/03	PCT (Exhibit 2);		
EP	0	3	2	2	2	4	2	6/28/89	EPO;		
EP	0	5	1	4	5	4	0	11/25/92	EPO;		
EP	0	6	8	2	0	2	7	11/15/95	EPO;		
EP	0	7	2	9	7	5	8	9/4/96	EPO;		
EP	0	7	7	3	0	2	3	5/14/97	EPO;		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
EXAMINER				DATE CONSIDERED							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office						Atty. Docket No. 60390-IB/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								Applicants: Arlindo Castelhano et al.	
								Filing Date Herewith	Group
U.S. PATENT DOCUMENTS									
Examiner Initial		Document Number			Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS									
		Document Number			Date	Country	Class	Subclass	Translation
									Yes No
GB	0 9 1 5 3 0 3				1/9/63	Great Britain;			
DE	3 1 4 5 2 8 7				5/19/93	Germany;			
IN	0 1 5 7 2 8 0				2/22/86	India;			
JP	09 2 9 1 0 8 9				5/11/999	Japan;			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
		Abbracchio M., et al., (1999) "Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases", <i>Ann. NY. Acad. Sci.</i> , 890: 79-92;							
		Banker, G.S. et al., <i>Modern Pharmaceutics</i> , 3 rd ed., Marcel Dekker, New York, 1996, page 596;							
		Barrett, R.J. (1996) "Realizing the Potential of Adenosine-Receptor-Based Therapeutics" <i>Proc. West. Pharmacol. Soc.</i> 39: 61-66;							
		Barrett, R.J. et al., "N-0861 selectively antagonizes adenosine A1 receptors in vivo" <i>European J. Pharmacology</i> (1992) 216: 9-16;							
		Brand A., et al., (2001) "Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical neurons", <i>Neuropharmacology</i> , 40: 85-95;							
		Bundy, G.L. et al. (1995) "Synthesis of Novel 2,4-Diaminopyrrolo-[2,3-d]pyrimidines with Antioxidant, Neuroprotective, and Antiasthma Activity" <i>J. Med. Chem.</i> 38: 4161-4163;							
		Campbell, R.M. et al., "Selective A ₁ -Adenosine Receptor Antagonists Identified Using Yeast <i>Saccharomyces Cerevisiae</i> Functional Assays" <i>Bioorg. & Med. Chem. Lett.</i> (1999) 9(16): 2413-2418;							
		Chen, Y. L., et al., "Synthesis and Oral Efficacy of a 4-(Butylethylamino)pyrrolo[2,3-d]pyrimidine: A Centrally Active Corticotropin-Releasing Factor ₁ Receptor Antagonist", (1997) <i>J. Med. Chem.</i> , 40: 1749-1754;							
		Cummings, J. et al., "Antagonism of the Cardiodepressant Effects of Adenosine during Acute Hypoxia" <i>Academic Emergency Medicine</i> (2000), 7(8): 618-624;							
		DeNinno, M.P. in <i>Annual Reports in Medicinal Chemistry</i> , Vol. 33, (Academic Press: San Diego, 1998), pp. 111-120;							
		Dhainaut, A. et al., "New Purines and Purine Analogs as Modulators of Multidrug Resistance" <i>J. Med. Chem.</i> (1996) 39: 4099-4108;							
		Dooley, M.J. et al., "Theoretical Structure-Activity Studies of Adenosine A1 Ligands: Requirements for Receptor Affinity" <i>Bioorg. Med. Chem.</i> (1996), 4(6): 923-934;							
		Feoktistove, I. et al., (1998) "Adenosine A _{2B} receptors: a novel therapeutic target in asthma?", <i>TiPS</i> 19: 148-153;							
		Gao, E. et al., "Adenosine A1 Receptor Antagonist Prolongs Survival in the Hypoxic Rat" <i>J. Cardiovascular Pharm.</i> (2001) 38: 384-394;							
EXAMINER					DATE CONSIDERED				
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>									

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 60390-IB/JPW/GJG/JBC	Serial No. Not Yet Known	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			Applicants: Arlindo Castelhano et al.				
			Filing Date Herewith	Group			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Hart, H. et al., <u>Organic Chemistry, A Short Course</u> , (Houghton Mifflin: 1995), p. 121;					
		Iwamura, H. et al. (1996) "Quantitative Aspects of the Receptor Binding of Cytokinin Agonists and Antagonists" <u>J. Med. Chem.</u> , 26: 838-844;					
		Jacobson K.A., et al., (1998) "Adenosine A3 receptors: novel ligands and paradoxical effects", <u>TiPS</u> , 19:184-191;					
		Jacobson K.A., et al., (1997) "Pharmacological Characterization of Novel A3 Adenosine Receptor-selective Antagonists", <u>Neuropharmacology</u> , 36 (9): 1157-1165;					
		Jorgensen, A. et al. (1985) "Synthesis of 7H-Pyrrolo[2,3-d]pyrimidin-4-amines" <u>Liebigs Ann. Chem.</u> , Pages 142-148;					
		Kaiser, S.M. and R.J. Quinn (1999) "Adenosine receptors as potential therapeutic targets" <u>Drug Discovery Today</u> 4(12): 542-551;					
		Kiichiro, K. et al. "Synthesis of pyrazinecarboxylic acid derivs. - (II) derivs. of 3-aminopyrazinecarboxylic acid" (1961) <u>Yakugaku Zasshi</u> 81: 1650-1653;					
		Lee T., et al., (1999) "Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors", <u>72nd Scientific Sessions of the American Heart Association</u> , Atlanta, GA, p.197;					
		Lee T., et al., (2000) "Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors", <u>Am. J. Physiol. Renal Physiol.</u> , 278: F380-F387;					
		Marx, D. et al. (2001) "Therapy of Bronchial Asthma with Adenosine Receptor Agonists or Antagonists" <u>Drug News Perspect.</u> 14(2): 89-100;					
		Mautner, H.G., (1961) "Potential Deoxyribonucleic Acid Cross-linking Agents. 8,8'-Bispurines", <u>J. Org. Chem.</u> 26(6):1914-1917;					
		Muller, C. E. et al. (1990) "7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A1 Selective Adenosine Receptor Antagonists" <u>J. Med. Chem.</u> , 33: 2822-2828;					
EXAMINER		DATE CONSIDERED					
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 60390-IB/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)						Applicants: Arlindo Castelhano et al.	
						Filing Date Herewith	Group
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Muller, C.E. et al. (1996) "Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A ₁ -Adenosine Receptor Antagonists" <i>J. Med. Chem.</i> , 39: 2482-2491;					
		Muller, C. E. and Stein, B. (1996) "Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications", <i>Current Pharmaceutical Design</i> , 2: 501-530;					
		Muller, C. E. (1997) "A ₁ -Adenosine Receptor Antagonists", <i>Exp. Opin. Ther. Patents</i> 7(5): 419-440;					
		Muller, C. E., et al., (1997) "Synthesis and Structure-Activity Relationships of 3,7-Dimethyl-1-propargylxanthine Derivatives, A _{2A} -Selective Adenosine Receptor Antagonists", <i>J. Med. Chem.</i> , 40: 4396-4405;					
		Nishiyama, A. et al., "Adenosine A1 Receptor Antagonist KW-3902 Prevents Hypoxia-Induced Renal Vasoconstriction" <i>J. Pharm. Exp. Ther.</i> (1999), 291: 988-993;					
		Nyce, J. W. and Metzger, J.W., (1997) "DNA antisense therapy for asthma in an animal model", <i>Nature</i> , 385: 721-725;					
		Pichler, H. et al. "Synthese von 7-unsubstituierten 7H-Pyrrolo[2,3-d] pyrimidinen", (1986) <i>Liebigs Ann. Chemie.</i> , 9: 1485-1505;					
		Seela, F., and Lupke, U., "Mannich-Reaktion am 2-Amino-3,7-dihydropyrrolo [2,3-d] pyrimidin-4-on, dem Chromophor des Ribonucleosids "Q" (1977) <i>Chem. Ber.</i> 110: 1462-1469;					
		Shan, Daxian et al., <i>J. Pharmaceutical Sci.</i> , (1997) 86:765-767;					
		Szkotak, A.J. et al., "Regulation of K ⁺ current in human airway epithelial cells by exogenous and autocrine adenosine" <i>Am. J. Physiol. Cell Physiol.</i> (2001), 281: C1991-C2002;					
		Venugopalan, B. et al. (1998) "Synthesis of 6,7-Dimethoxypyrimido[4,5-b]-indoles as Potential Antihypertensive Agents" <i>J. Heterocyclic Chem.</i> , 25: 1633-1639;					
		Welch, W.J. "Adenosine type 1 receptor antagonists in fluid retaining disorders" <i>Expert Opin. Investig. Drugs</i> (2002), 11(11): 1553-1562;					
		West, R. A. et al. (1961) "2-Alkyl(aryl)-and 2,7-Dimethyl-4-substituted Aminopyrrolo[2,3-d]pyrimidines" <i>J. Org. Chem.</i> , 26: 3809-3812;					
EXAMINER			DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office							Atty. Docket No. 60390-IB/JPW/GJG/JBC	Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									Applicants: Arlindo Castelhano et al.	
									Filing Date Herewith	Group
U.S. PATENT DOCUMENTS										
Examiner Initial		Document Number				Date	Name	Class	Subclass	Filing Date if Appropriate
		20	02	00	28	7	8	2	3/7/02	Castelhano et al. (Exhibit 3, claims only);
		20	02	00	58	6	6	7	5/16/02	Castelhano et al. (Exhibit 4, claims only);
		20	03	00	36	5	4	5	2/20/03	Castelhano et al. (Exhibit 5, claims only);
		20	02	00	94	9	7	4	4/17/03	Castelhano et al. (Exhibit 6, claims only);
		20	03	00	73	7	0	8	4/17/03	Castelhano et al. (Exhibit 7, claims only);
		09	4	5	4	0	7	4	12/2/99	Castelhano et al. (Exhibit 8, claims only);
		09	4	5	4	0	7	5	12/2/99	Castelhano et al. (Exhibit 9, claims only);
		10	0	1	0	0	9	2	11/30/01	Castelhano et al.;
		20	03	00	45	5	3	6	3/6/03	Castelhano et al. (Exhibit 10, claims only);
FOREIGN PATENT DOCUMENTS										
		Document Number				Date	Country	Class	Subclass	Translation
										Yes
										No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)										
		Williams, E. F. et al., "Nucleoside transport sites in a cultured human retinal cell line established by SV-40 T antigen gene", (1994) <u>Current Eye Research</u> , 13: 109-118;								
		Wolff, Manfred E., <u>Burger's Medicinal Chemistry and Drug Discovery</u> , 5 th ed., Volume I: Principles and Practice, John Wiley & Sons, 1995, pages 975-977;								
		Woods, C. L. and Blazynski, C. (1991) "Characterization of Adenosine A ₁ -receptor Binding Sites in Bovine Retinal Membranes", <u>Experimental Eye Research</u> , 53: 325-331; and								
		Zhao, Z. et al., "Bioactivation of 6,7-Dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) to Reactive Intermediates that Bind Covalently to Macromolecules and Produce Genotoxicity" <u>Chem. Res. Toxicol.</u> , (1996) 9: 1230-1239.								
EXAMINER					DATE CONSIDERED					
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										